Yonsei University: Carcinoma, Non-Small-Cell Lung trials

The registry lists 25 Carcinoma, Non-Small-Cell Lung studies with Yonsei University as lead sponsor. 6 are open to participants now and 0 have results posted.

Phase 1 1Phase 2 21Phase 3 1No phase 3(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Collaborative Clinical-translational Cohort of Amivantamab Plus Lazertinib and Amivantamab Plus Chemotherapy in Patients With EGFR-mutant, Locally Advanced or Metastatic/Recurrent Non-Small Cell Lung Cancer (INSTAR Study)Not yet recruitingNCT07507188Phase 2
• Efficacy and Safety of T-DXd in HER2-mutant Advanced Lung Cancer Patients With Asymptomatic Brain MetastasesEnrolling by invitationNCT06250777Phase 2
• Lazertinib and Chemotherapy Combination in EGFR-mutant NSCLC Patients Without ctDNA Clearance After lead-in Lazertinib MonotherapyNot yet recruitingNCT06020989Phase 2
• An Open-label, Phase 2trial of Sotorasib in KRAS G12C-mutant Non-small-cell Lung Cancer(NSCLC) Patients and a Translational Study to Find Acquired Resistance Mechanism to SotorasibNot yet recruitingNCT05451056Phase 2
• The Safety and Efficacy of First-line Lazertinib and Locally Ablative Radiotherapy in Patients With Synchronous Oligo-metastatic EGFR-mutant Non-small Cell Lung CancerNot yet recruitingNCT05167851Phase 2
• A Window of Opportunity Study for Investigating Drug Tolerant Persister (DTP) to Neoadjuvant Osimertinib in Resectable Non-small Cell Lung Cancer (NSCLC) Harbouring EGFR MutationsRecruitingNCT04816838Not applicable
• Neoadjuvant Lazertinib With or Without Chemotherapy for Patients With EGFR-mutated Resectable Non-small Cell Lung CancerActive, not recruitingNCT06268210Phase 2
• Lazertinib+Pemetrexed/Carboplatin in Patients With EGFR Sensitizing Mutation Positive Recurrent or Metastatic Non-Small Cell Lung Cancer Failed to Prior LazertinibCompletedNCT05786430Phase 2
• A Window of Opportunity Study for Investigating Drug Tolerant Persister (DTP) to Preoperative Brigatinib in Resectable Non-small Cell Lung Cancer (NSCLC) Harboring ALK Fusions.Status unknownNCT05361564Phase 2
• Lazertinib for Patients With NSCLC Harboring Uncommon EGFR MutationsStatus unknownNCT05277701Phase 2
• Window of Opportunity Trial of Durvalumab (MEDI4736) to Identify Immune Dynamics in Operable Non-small Cell Lung Cancer (NSCLC) (MIRACLE)Active, not recruitingNCT05206812Phase 2
• Study of Stereotactic Ablative Radiotherapy(SBRT) Followed by Atezolizumab / Tiragolumab in Treatment-naive Patients With Metastatic Non-small Cell Lung CancerStatus unknownNCT05034055Phase 2
• A Study for Identification of Predictive Immune Biomarker for Atezolizumab Therapy in NSCLC PatientsCompletedNCT04312308
• Clinical Trial for Evaluating Efficacy and Safety of PDR001 in Concurrent Plus Consolidation Versus Consolidation Only in Addition to Standard Chemoradiotherapy in Unresectable Stage III NSCLC Patients (PASTURE)WithdrawnNCT03945227Phase 2
• A Study for Identification of Predictive Immune Biomarker in Peripheral Blood for Nivolumab Therapy in NSCLC PatientsCompletedNCT03486119
• A Study of LDK378 in Patients With Non-small Cell Lung Cancer Harboring ROS1 RearrangementStatus unknownNCT03399487Phase 2
• A Phase III, Randomized, Multi-center Study to Determine the Efficacy of the Intercalating Combination Treatment of Chemotherapy and Gefitinib or Chemotherapy as Adjuvant Treatment in NSCLC With Common EGFR Mutations.Status unknownNCT03381066Phase 3
• An Open-label Phase Ib/II Study of BAY 1000394 (Roniciclib) in Combination With Docetaxel in Second- or Third-line Treatment of Patients With Advanced Non-small Cell Lung Cancer (NSCLC)WithdrawnNCT02522910Phase 1/2
• An Open-label, Multicenter, Phase II Study of LDK378 in Patients With Non-small Cell Lung Cancer Harboring ROS1 RearrangementCompletedNCT01964157Phase 2
• Genotype-Driven Treatment of Advanced Non-small Cell Lung Cancer Based on mRNA Expression of ERCC1 & RRM1 as First-line ChemotherapyCompletedNCT01648517Phase 2
• Phase II Study of Gefitinib Plus Nimotuzumab Versus Gefitinib in Non-small Cell Lung CancerCompletedNCT01498562Phase 2
• Sorafenib and Erlotinib in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer That Has Not Responded to ChemotherapyStatus unknownNCT00801385Phase 2
• First-Line Combination Chemotherapy in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer That Cannot Be Removed by SurgeryStatus unknownNCT00736814Phase 2
• Combination Chemotherapy and Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed by SurgeryStatus unknownNCT00616785Phase 2
• Gefitinib in Treating Patients With Stage IIIA Non-Small Cell Lung CancerStatus unknownNCT00616499Phase 2